Associated tags: Radiology, Medical Devices, Research, Health, SHI, Oncology, Hospital, Pharmaceutical industry, Fukushima Medical University, Halogen, AF, Isotope, Osaka University, Society, Mission, Head, Astatine, Atomic, Proton therapy, Hospitals
Locations: JAPAN, TAIWAN, ASIA PACIFIC, TOKYO, SWEDEN
Radiology,
Professional Services,
Pharmaceutical,
Oncology,
Start-Up,
Medical Devices,
University,
Other Manufacturing,
Education,
Clinical Trials,
Manufacturing,
Health,
Acceleration,
Nuclear medicine,
Nature,
Japan Science and Technology Agency,
Ris,
Kita,
Radiopharmaceutical,
Targeted alpha-particle therapy,
TAT,
Research,
Thyroid cancer,
Technology Agency of the Czech Republic,
Bismuth,
OPERA,
RI,
SHI,
Drug discovery,
JST,
Fukushima Medical University,
Multimedia,
Halogen,
AF,
Isotope,
Osaka University,
Mission,
Head,
Pharmaceutical industry,
Atomic,
Astatine Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
Key Points:
- Sumitomo Heavy Industries, Ltd. (“SHI”) (TOKYO:6302) (Head Office: Shinagawa-ku, Tokyo, President and CEO: Shinji Shimomura) announced the decision to invest in Alpha Fusion Inc. (“AF”) (Head Office: Kita-ku, Osaka, Chief Executive Officer: Sunao Fujioka), a developer of Astatine based radiopharmaceuticals for Targeted Alpha Therapy (“TAT”).
- View the full release here: https://www.businesswire.com/news/home/20230308005372/en/
Image Diagram of TAT (Graphic: Business Wire)
AF will aim at establishing their pipeline (*1).
- Development of their radiopharmaceuticals is expected to be progressed by this funding and will lead more needs of Astatine-211.
- Astatine-211 (211At, Atomic number 85, Half life time 7.2H) is an element belonging to halogens and has the property of emitting alpha particle.
Oncology,
Health,
Medical Devices,
Technology,
Hospitals,
Radiology,
Hardware,
Proton,
Neoplasm,
CT,
FLASH,
Research,
Cancer,
SHI,
Patient,
Multimedia,
Proton therapy,
Hospital,
Society,
Medical imaging Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (head office: Shinagawa City, Tokyo; President and CEO: Shinji Shimomura; hereinafter "SHI") has received an order from Taichung Veterans General Hospital (Taiwan) for a next-generation proton therapy system (*).
Key Points:
- Sumitomo Heavy Industries, Ltd. (TOKYO:6302) (head office: Shinagawa City, Tokyo; President and CEO: Shinji Shimomura; hereinafter "SHI") has received an order from Taichung Veterans General Hospital (Taiwan) for a next-generation proton therapy system (*).
- The next-generation system will be installed at a new proton therapy center to be established in Taichung City, Taiwan, and proton therapy is scheduled to begin in 2026.
- Taichung Veterans General Hospital is a national hospital located in central Taiwan and provides safe and high-quality medical services with new medical technologies and outstanding talents.
- Taichung Veterans General Hospital plans to conduct research on new treatment technologies, such as FLASH, in collaboration with SHI.